Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice. - Wikidata - wikimedia - TriplyDB

Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice.

Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice.

http://www.wikidata.org/entity/Q35835882

about

Accelerated atherosclerosis in patients with SLE--mechanisms and management Unmet medical needs in systemic lupus erythematosus Cardiovascular disease in lupus: insights and updates The effect of mycophenolate mofetil on disease development in the gld.apoE (-/-) mouse model of accelerated atherosclerosis and systemic lupus erythematosus Mycophenolate mofetil enhances the negative effects of sirolimus and tacrolimus on rat kidney cell metabolism Dysregulated CD4+ T cells from SLE-susceptible mice are sufficient to accelerate atherosclerosis in LDLr-/- mice.Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions.Atherosclerosis in systemic lupus erythematosus.Systems Biology and Noninvasive Imaging of Atherosclerosis.Cardiovascular risk in pediatric-onset rheumatological diseases.Accelerated atherosclerosis in SLE: mechanisms and prevention approaches.Transient ischemic attack and stroke in systemic lupus erythematosus.Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies.Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: a literature review.Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk.Mycophenolic acid attenuates the tumour necrosis factor-α-mediated proinflammatory response in endothelial cells by blocking the MAPK/NF-κB and ROS pathways.Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.Progression of noncalcified and calcified coronary plaque by CT angiography in SLE.Impact of Disease Duration on Vascular Surrogates of Early Atherosclerosis in Childhood-Onset Systemic Lupus Erythematosus.Expanding the therapeutic frontier in atherosclerosis.Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis.Immune modulatory effects of statins.

P2860

Q26820245-280ED32C-4665-4445-A79B-1B1362DCDA9F Q27005906-002517E1-9BEF-431E-8775-23D32723C087 Q27016554-4CF33678-0C88-4568-87EE-5915760D4B53 Q28486062-3572374B-A143-43CF-8FC9-8D7E23E0FAD7 Q28539334-F9141F01-A47F-425D-865F-CD667F2EE507 Q30405805-817B873E-12AD-449A-92FF-2339D2F675A3 Q34343906-A37BB05A-20C7-403A-A37B-DE4CB0C9643E Q35121150-B1C5FF33-25F0-426C-B63D-666B75E298A1 Q35525108-58B591E0-3A40-4E6F-8234-E007C0B559AD Q36884545-1F5BFA13-29D9-4638-B150-FA1811D5E43B Q36903089-D7B5B2F6-07C9-49B6-B240-ADFF78075916 Q37658524-E993FD5C-8441-4411-AB58-CE1CF5BDC6FD Q38149851-B03426D3-91B9-4C4C-8F19-BA9E54B9B078 Q38175493-EC861DDF-B502-427D-ABA5-BE538B4BF98F Q38554636-ADDA815D-07CF-4339-97F5-B113A9BE0D5B Q38737288-23D4F881-39A6-4A61-8F84-D21779D4FE67 Q39077512-6CA5D0D5-D075-4B42-B22D-9F1A5E779B47 Q39150632-9B9E6F10-068B-4631-9A2B-B9664A4DD5D5 Q40459284-A2684265-6B00-4611-B13E-FF4916E3829F Q40549097-C1260002-0096-4A0F-A25B-73C8F4354970 Q42734507-F68CE5D5-6FAD-4B5B-BDEF-B27F79B9E8CC Q50052184-D10DD016-504B-496D-86F5-C66F7B5A6330 Q50214328-C8047F0A-56F2-4AF5-AE42-20ED50370A32

P2860

Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice.

http://www.wikidata.org/entity/Q35835882

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Mycophenolate mofetil but not ...... in lupus-prone LDLr(-/-) mice.

@ast

Mycophenolate mofetil but not ...... in lupus-prone LDLr(-/-) mice.

@en

type

label

Mycophenolate mofetil but not ...... in lupus-prone LDLr(-/-) mice.

@ast

Mycophenolate mofetil but not ...... in lupus-prone LDLr(-/-) mice.

@en

prefLabel

Mycophenolate mofetil but not ...... in lupus-prone LDLr(-/-) mice.

@ast

Mycophenolate mofetil but not ...... in lupus-prone LDLr(-/-) mice.

@en

P1433

Q35835882-E253B705-B8C0-4B8D-BB1E-BFBFA3CFD9F5

P1476

Q35835882-36AAFDF4-8DAF-48E1-8628-C47CA7B38230

P2093

Q35835882-404C8C2C-4C17-43EA-8990-5D50CD48E3E1

Q35835882-7B618D71-E839-4511-B883-40DB0EE8684E

Q35835882-7E18225C-EC07-48A7-BB0D-6A4B1A9A43A4

Q35835882-7EF9B55D-26E5-4F2B-8B8B-7EF6E01594D7

Q35835882-7FDC2F16-819A-42BA-BBA8-CA9ECCE173B6

Q35835882-B87EB129-6A60-41A2-9C9C-C7956AFDDCF9

Q35835882-BDD433B1-1EFC-426A-814F-B908E947FEFA

Q35835882-BF8B8080-6368-4061-A71B-3E69AE004BBD

Q35835882-D2EC4983-C46E-4A3D-9D59-1519C2E62161

P2860

Q35835882-0E58C842-DB63-49C1-8943-2EACD40CB568

Q35835882-1182270A-BE18-43B5-88A5-03C512E2D866

Q35835882-1856E241-8B2E-4705-8B7F-E1193130CA59

Q35835882-1D183677-2450-43F0-B20B-2E0D240657DD

Q35835882-203C46A8-35E4-4975-937F-E87B9A50634C

Q35835882-424AD001-4346-45ED-BCBC-07ECF53146A2

Q35835882-53215084-1335-44C3-AE85-8EF3EF3D69DA

Q35835882-5D137842-C488-47FF-9CC8-959F67762C39

Q35835882-5F901185-8107-43DC-86CA-9DA594224F68

Q35835882-62A398BF-27F3-4F73-BEBE-D16F5EEC01B2

P304

Q35835882-1B5AB459-8AEE-4458-A327-75CA40CD7840

P31

Q35835882-5DB4E3D0-2FCD-440E-B13E-0B1AAAB2EFF3

P356

Q35835882-B5BF2B7E-5D82-4245-80E5-A3C852F6A123

P407

Q35835882-2B0FDBF5-03FF-43A8-AF27-2B7D4123DB2D

P433

Q35835882-9B1B2CC1-94CF-4063-8509-6B4A190C7BD9

P478

Q35835882-DAC080DE-9441-4930-B758-F2993181FAD0

P577

Q35835882-15D73F1C-5144-4E72-AEC4-0ED80AEF7F57

P5875

Q35835882-0CB5BDC5-0244-4B72-B442-4FF4027CFB02

P698

Q35835882-8C348DC1-8886-46A4-933F-71DD0CF0341E

P921

Q35835882-605129CE-A27A-446F-AF93-48E9F3B245E9

P932

Q35835882-CFA46C5B-68C7-4C90-A80C-BC22E68292B5

P356

ANNRHEUMDIS-2011-200071

P1433

Annals of the Rheumatic Diseases

P1476

Mycophenolate mofetil but not ...... in lupus-prone LDLr(-/-) mice.

@en

P2093

Amy S Major

http://www.w3.org/2001/XMLSchema#string

Ashley J Wilhelm

http://www.w3.org/2001/XMLSchema#string

Curtis L Gabriel

http://www.w3.org/2001/XMLSchema#string

Erik S Stroes

http://www.w3.org/2001/XMLSchema#string

John J Kastelein

http://www.w3.org/2001/XMLSchema#string

Nekeithia S Wade

http://www.w3.org/2001/XMLSchema#string

Paul P Tak

http://www.w3.org/2001/XMLSchema#string

Sander I van Leuven

http://www.w3.org/2001/XMLSchema#string

Yanice V Mendez-Fernandez

http://www.w3.org/2001/XMLSchema#string

P2860

Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus

Pathogenic mechanisms in systemic lupus erythematosus.

Mycophenolate mofetil and its mechanisms of action.

B cell depletion reduces the development of atherosclerosis in mice.

Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice.

Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus

Systemic inflammation as a risk factor for atherothrombosis.

Mycophenolate mofetil and atherosclerosis: results of animal and human studies.

Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association.

Cardiac involvement in systemic rheumatic diseases: An update.

P304

408-414

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2011-200071

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51667991

http://www.w3.org/2001/XMLSchema#string

P698

21953346

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

3306213

http://www.w3.org/2001/XMLSchema#string